Abstract
Cisplatin in combination with vindesine has been widely used for the treatment of advanced non-small-cell lung cancer (NSCLC), producing an overall response rate of 32%. We conducted a phase II study to examine whether the addition of carboplatin to the combination of cisplatin and vindesine would improve the antitumor activity of the two platinum agents in advanced NSCLC without increasing their toxicity. Carboplatin (240 mg/m2) and vindesine (3 mg/m2) were given intravenously on day 1 and cisplatin (60 mg/m2) and vindesine (3 mg/m2), on day 8. Of the 40 evaluable patients with advanced NSCLC, 12 showed a partial response, for an overall response rate of 30% (95% confidence interval, 17%–47%). The median duration of response was 12 weeks, and the median survival duration for all patients was 38 weeks. The major toxicity was hematologic: leukopenia (WHO grade≥3) was observed in 21 patients (53%) and anemia (WHO grade≥3), in 13 patients (33%). However, thrombocytopenia was mild and WHO grade 3 toxicity was observed in only 4 patients (10%). Nonhematologic toxicities consisted mainly of WHO grade≥2 nausea and vomiting in 16 patients (40%) and WHO grade≥2 alopecia in 11 patients (28%). No significant nephrotoxicity or neurotoxicity was seen. Our findings indicate that the addition of carboplatin to the combination of cisplatin and vindesine does not improve antitumor activity in patients with advanced NSCLC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bakowski MT, Crouch JC (1983) Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat Rev 10: 159
Belani CP, Egorin MJ, Abrams JS, Hiponia D, Eisenberger M, Aisner J, Van Echo DA (1989) A novel pharmacodynamically based approch to dose optimization of carboplatin when used in combination with etoposide. J Clin Oncol 7: 1896
Bunn PA Jr (1989) The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol 16 [Suppl 6]: 10
Bunn PA Jr (1992) Clinical experiences with carboplatin (Paraplatin) in lung cancer. Semin Oncol 19 [Suppl 2]: 1
Donnadieu N, Paesmans M, Sculier JP (1991) Chemotherapy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature. Lung Cancer 7: 243
Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction ofcis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 44: 5432
Gandara DR, Wold H, Perez EA, Deisseroth AB, Doroshow J, Meyers F, Mcwhirter K, Hannigan J, De Gregorio MW (1989) Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst 81: 790
Gralla RJ, Casper ES, Kelsen DP, Braun DW Jr, Dukeman ME, Martini N, Young CW, Golbey RB (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 95: 414
Japan Cooperative Oncology Group on Lung Cancer (1990) Phase II study of carboplatin in patients with nonresectable lung cancer. Cancer Chemother Pharmacol 26: 101
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457
Kreisman H, Goutsou M, Modeas C, Graziano SL, Costanza ME, Green MR (1990) Cisplatin-carboplatin therapy in extensive nonsmall cell lung cancer: a Cancer and Leukemia Group B study. Eur J Cancer 26: 1057
Lund B, Hansen M, Hansen OP, Hansen HH (1989) High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 7: 1469
Muggia FM (1989) Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin Oncol 16 [Suppl 5]: 7
Niitani H, Kobayashi K (1992) Cisplatin/carboplatin therapy in nonsmall cell lung cancer. Oncology 49 [Suppl 1]: 51
Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC (1984) High-dose cisplatin in hypertonic saline. Ann Intern Med 100: 19
Ozols RF, Ostchega Y, Myers CE, Young RC (1985) High-dose cisplatin in hypenonic saline in refratory ovarian cancer. J Clin Oncol 3: 1246
Piccart MJ, Nogaret JM, Marcelis L, Longrée H, Ries F, Kains JP, Gobert P, Domange AM, Sculier JP, Gompel C, the Belgian Study Group for Ovarian Carcinoma (1990) Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. J Natl Cancer Inst 82: 703
Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tominaga K, Sakurai M, Suga J, Miyaoka H, Sano T, Keicho N, Takahashi H, Ishihara J, Tamura T, Hoshi A, Jett JR (1986) Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res 77: 782
Sculier JP, Klastersky J, Giner V, Bureau G, Thiriaux J, Efremidis A, Berchier MC, Kroll F, Ries F, Mommen P, Paesmans M (1992) A combination of 60 mg/m2 cisplatin (CDDP) and 200 mg/m2 carboplatin (CBDCA) is as active but less nephrotoxicic than 120 mg/m2 CDDP in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 11: 289
Van Glabbeke M, Renard J, Pinedo HM, Cavalli F, Vermorken J, Sessa C, Abele R, Clavel M, Monfardini S (1988) Iproplatin and carboplatin induced toxicities: overview of a phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG). Eur J Cancer Clin Oncol 24: 255
World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO Offset Publication 48. World Health Organization, Geneva
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saito, H., Shimokata, K., Saka, H. et al. Phase II study of carboplatin, cisplatin, and vindesine in advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 33, 154–156 (1993). https://doi.org/10.1007/BF00685334
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685334